User login
Data Trends 2023: Migraine and Headache
22. Seng EK et al. Neurology. 2022;99(18):e1979-e1992. doi:10.1212/WNL.0000000000200888
23. Coffman C et al. Neurology. 2022;99(2):e187-e198. doi:10.1212/WNL.0000000000200518
24. Hesselbrock RR et al. Aerosp Med Hum Perform. 2022;93(1):26-31. doi:10.3357/amhp.5980.2022
25. Kuruvilla DE et al. BMC Complement Med Ther. 2022;22(1):22. doi:10.1186/s12906-022-03511-6
22. Seng EK et al. Neurology. 2022;99(18):e1979-e1992. doi:10.1212/WNL.0000000000200888
23. Coffman C et al. Neurology. 2022;99(2):e187-e198. doi:10.1212/WNL.0000000000200518
24. Hesselbrock RR et al. Aerosp Med Hum Perform. 2022;93(1):26-31. doi:10.3357/amhp.5980.2022
25. Kuruvilla DE et al. BMC Complement Med Ther. 2022;22(1):22. doi:10.1186/s12906-022-03511-6
22. Seng EK et al. Neurology. 2022;99(18):e1979-e1992. doi:10.1212/WNL.0000000000200888
23. Coffman C et al. Neurology. 2022;99(2):e187-e198. doi:10.1212/WNL.0000000000200518
24. Hesselbrock RR et al. Aerosp Med Hum Perform. 2022;93(1):26-31. doi:10.3357/amhp.5980.2022
25. Kuruvilla DE et al. BMC Complement Med Ther. 2022;22(1):22. doi:10.1186/s12906-022-03511-6
Data Trends 2023: Parkinson’s Disease
17. US Department of Veterans Affairs, Office of Research and Development.
Parkinson’s disease. Updated October 28, 2021. Accessed May 5, 2023.
https://www.research.va.gov/topics/parkinsons.cfm
18. Feeney M et al. Front Neurol. 2022;13:924999. doi:10.3389/fneur.2022.924999
19. Heronemus M et al. Parkinsonism Relat Disord. 2022;105:58-61. doi:10.1016/j.parkreldis.2022.11.003
20. Nejtek VA et al. PLoS One. 2021;16(11):e0258851. doi:10.1371/journal.pone.0258851
21. Yang Y et al. Dement Neurocogn Disord. 2016;15(3):75-81. doi:10.12779/dnd.2016.15.3.75
17. US Department of Veterans Affairs, Office of Research and Development.
Parkinson’s disease. Updated October 28, 2021. Accessed May 5, 2023.
https://www.research.va.gov/topics/parkinsons.cfm
18. Feeney M et al. Front Neurol. 2022;13:924999. doi:10.3389/fneur.2022.924999
19. Heronemus M et al. Parkinsonism Relat Disord. 2022;105:58-61. doi:10.1016/j.parkreldis.2022.11.003
20. Nejtek VA et al. PLoS One. 2021;16(11):e0258851. doi:10.1371/journal.pone.0258851
21. Yang Y et al. Dement Neurocogn Disord. 2016;15(3):75-81. doi:10.12779/dnd.2016.15.3.75
17. US Department of Veterans Affairs, Office of Research and Development.
Parkinson’s disease. Updated October 28, 2021. Accessed May 5, 2023.
https://www.research.va.gov/topics/parkinsons.cfm
18. Feeney M et al. Front Neurol. 2022;13:924999. doi:10.3389/fneur.2022.924999
19. Heronemus M et al. Parkinsonism Relat Disord. 2022;105:58-61. doi:10.1016/j.parkreldis.2022.11.003
20. Nejtek VA et al. PLoS One. 2021;16(11):e0258851. doi:10.1371/journal.pone.0258851
21. Yang Y et al. Dement Neurocogn Disord. 2016;15(3):75-81. doi:10.12779/dnd.2016.15.3.75
Data Trends 2023: Limb Loss and Prostheses
- US Department of Veterans Affairs. Amputation system of care [fact sheet]. Published December 2022. Accessed April 21, 2023. https://www.prosthetics.va.gov/factsheet/ASoC-FactSheet.pdf
- US Department of Veterans Affairs, Office of the Inspector General. Veteran Affairs Inspector General healthcare inspection: prosthetic limb care in VA facilities. Published March 8, 2012. Accessed April 21, 2023. https://www.va.gov/oig/pubs/VAOIG-11-02138-116.pdf
- Department of Veterans Affairs; Department of Defense. Clinical Practice Guideline for the Management of Upper Limb Amputation Rehabilitation. Patient Summary. Published March 2022. Accessed April 10, 2023. https://www.healthquality.va.gov/guidelines/Rehab/ULA/VADoDULACPG_PatientSummary_Final_508.pdf
- US Government Accountability Office, Report to Congressional Committees. Veterans Health Care: Agency efforts to provide and study prosthetics for small but growing female veteran population. Published November 2020. Accessed April 21, 2023. https://www.gao.gov/assets/gao-21-60.pdf
- 117th Congress. Access to Assistive Technology and Devices for Americans Study Act or the Triple A Study Act (H.R.2461). April 13, 2021. Accessed April 21, 2023. https://www.congress.gov/bill/117th-congress/housebill/2461
- Russell Esposito E, et al. Prosthet Orthot Int. 2023 Jan 2023. Online ahead of print. doi:10.1097/PXR.0000000000000192
- US Department of Veterans Affairs. Center for Limb Loss and MoBility. Updated January 27, 2022. Accessed April 21, 2023. https://www.amputation.research.va.gov/
- US Department of Veterans Affairs. Advanced Platform Technology Center. Accessed April 21, 2023. https://www.aptcenter.research.va.gov
- Sanchez-Bustamante C. Limb loss: DHA's three advanced rehab centers provide holistic care. Medicine and the Military. Published May 3, 2022. Accessed April 21, 2023. https://health.mil/News/Articles/2022/05/04/Limb-Loss-DHAs-Three-Advanced-Rehab-Centers-Provide-Holistic-Care
- Center for Neurorestoration and Neurotechnology. VA Providence Healthcare System. Accessed April 21, 2023. https://centerforneuro.org
- Webster JB. OPRA™ patient information sheet. US Department of Veteran Affairs, Rehabilitation and Prosthetic Services. Accessed April 21, 2023. https://www.rehab.va.gov/PROSTHETICS/asoc/resources/OPRA-PatientInformation.pdf
- Hoyt BW, et al. Expert Rev Med Devices. 2020;17(1):17-25. doi:10.1080/17434440.2020.1704623
- Ewing amputation in veterans with PAD undergoing BKA. ClinicalTrials.gov. Updated October 31, 2022. Accessed April 21, 2023. https://www.clinicaltrials.gov/ct2/show/NCT05437562
- US Department of Veterans Affairs. Amputation system of care [fact sheet]. Published December 2022. Accessed April 21, 2023. https://www.prosthetics.va.gov/factsheet/ASoC-FactSheet.pdf
- US Department of Veterans Affairs, Office of the Inspector General. Veteran Affairs Inspector General healthcare inspection: prosthetic limb care in VA facilities. Published March 8, 2012. Accessed April 21, 2023. https://www.va.gov/oig/pubs/VAOIG-11-02138-116.pdf
- Department of Veterans Affairs; Department of Defense. Clinical Practice Guideline for the Management of Upper Limb Amputation Rehabilitation. Patient Summary. Published March 2022. Accessed April 10, 2023. https://www.healthquality.va.gov/guidelines/Rehab/ULA/VADoDULACPG_PatientSummary_Final_508.pdf
- US Government Accountability Office, Report to Congressional Committees. Veterans Health Care: Agency efforts to provide and study prosthetics for small but growing female veteran population. Published November 2020. Accessed April 21, 2023. https://www.gao.gov/assets/gao-21-60.pdf
- 117th Congress. Access to Assistive Technology and Devices for Americans Study Act or the Triple A Study Act (H.R.2461). April 13, 2021. Accessed April 21, 2023. https://www.congress.gov/bill/117th-congress/housebill/2461
- Russell Esposito E, et al. Prosthet Orthot Int. 2023 Jan 2023. Online ahead of print. doi:10.1097/PXR.0000000000000192
- US Department of Veterans Affairs. Center for Limb Loss and MoBility. Updated January 27, 2022. Accessed April 21, 2023. https://www.amputation.research.va.gov/
- US Department of Veterans Affairs. Advanced Platform Technology Center. Accessed April 21, 2023. https://www.aptcenter.research.va.gov
- Sanchez-Bustamante C. Limb loss: DHA's three advanced rehab centers provide holistic care. Medicine and the Military. Published May 3, 2022. Accessed April 21, 2023. https://health.mil/News/Articles/2022/05/04/Limb-Loss-DHAs-Three-Advanced-Rehab-Centers-Provide-Holistic-Care
- Center for Neurorestoration and Neurotechnology. VA Providence Healthcare System. Accessed April 21, 2023. https://centerforneuro.org
- Webster JB. OPRA™ patient information sheet. US Department of Veteran Affairs, Rehabilitation and Prosthetic Services. Accessed April 21, 2023. https://www.rehab.va.gov/PROSTHETICS/asoc/resources/OPRA-PatientInformation.pdf
- Hoyt BW, et al. Expert Rev Med Devices. 2020;17(1):17-25. doi:10.1080/17434440.2020.1704623
- Ewing amputation in veterans with PAD undergoing BKA. ClinicalTrials.gov. Updated October 31, 2022. Accessed April 21, 2023. https://www.clinicaltrials.gov/ct2/show/NCT05437562
- US Department of Veterans Affairs. Amputation system of care [fact sheet]. Published December 2022. Accessed April 21, 2023. https://www.prosthetics.va.gov/factsheet/ASoC-FactSheet.pdf
- US Department of Veterans Affairs, Office of the Inspector General. Veteran Affairs Inspector General healthcare inspection: prosthetic limb care in VA facilities. Published March 8, 2012. Accessed April 21, 2023. https://www.va.gov/oig/pubs/VAOIG-11-02138-116.pdf
- Department of Veterans Affairs; Department of Defense. Clinical Practice Guideline for the Management of Upper Limb Amputation Rehabilitation. Patient Summary. Published March 2022. Accessed April 10, 2023. https://www.healthquality.va.gov/guidelines/Rehab/ULA/VADoDULACPG_PatientSummary_Final_508.pdf
- US Government Accountability Office, Report to Congressional Committees. Veterans Health Care: Agency efforts to provide and study prosthetics for small but growing female veteran population. Published November 2020. Accessed April 21, 2023. https://www.gao.gov/assets/gao-21-60.pdf
- 117th Congress. Access to Assistive Technology and Devices for Americans Study Act or the Triple A Study Act (H.R.2461). April 13, 2021. Accessed April 21, 2023. https://www.congress.gov/bill/117th-congress/housebill/2461
- Russell Esposito E, et al. Prosthet Orthot Int. 2023 Jan 2023. Online ahead of print. doi:10.1097/PXR.0000000000000192
- US Department of Veterans Affairs. Center for Limb Loss and MoBility. Updated January 27, 2022. Accessed April 21, 2023. https://www.amputation.research.va.gov/
- US Department of Veterans Affairs. Advanced Platform Technology Center. Accessed April 21, 2023. https://www.aptcenter.research.va.gov
- Sanchez-Bustamante C. Limb loss: DHA's three advanced rehab centers provide holistic care. Medicine and the Military. Published May 3, 2022. Accessed April 21, 2023. https://health.mil/News/Articles/2022/05/04/Limb-Loss-DHAs-Three-Advanced-Rehab-Centers-Provide-Holistic-Care
- Center for Neurorestoration and Neurotechnology. VA Providence Healthcare System. Accessed April 21, 2023. https://centerforneuro.org
- Webster JB. OPRA™ patient information sheet. US Department of Veteran Affairs, Rehabilitation and Prosthetic Services. Accessed April 21, 2023. https://www.rehab.va.gov/PROSTHETICS/asoc/resources/OPRA-PatientInformation.pdf
- Hoyt BW, et al. Expert Rev Med Devices. 2020;17(1):17-25. doi:10.1080/17434440.2020.1704623
- Ewing amputation in veterans with PAD undergoing BKA. ClinicalTrials.gov. Updated October 31, 2022. Accessed April 21, 2023. https://www.clinicaltrials.gov/ct2/show/NCT05437562
Data Trends 2023: Amyotrophic Lateral Sclerosis (ALS)
12. The ALS Association. ALS in the military. https://www.als.org/navigating-als/military-veterans/ALS-in-the-Military
13. McKay KA et al. Acta Neurol Scand. 2021;143(1):39-50. doi:10.1111/ane.13345
14. Lund EM et al. Muscle Nerve. 2021;63(6):807-811. doi:10.1002/mus.27181
15. Galea MD et al. Muscle Nerve. 2021;64(4):E18-E20. doi:10.1002/mus.27373
16. Re DB et al. J Neurol. 2022;269(5):2359-2377. doi:10.1007/s00415-021-10928-5
12. The ALS Association. ALS in the military. https://www.als.org/navigating-als/military-veterans/ALS-in-the-Military
13. McKay KA et al. Acta Neurol Scand. 2021;143(1):39-50. doi:10.1111/ane.13345
14. Lund EM et al. Muscle Nerve. 2021;63(6):807-811. doi:10.1002/mus.27181
15. Galea MD et al. Muscle Nerve. 2021;64(4):E18-E20. doi:10.1002/mus.27373
16. Re DB et al. J Neurol. 2022;269(5):2359-2377. doi:10.1007/s00415-021-10928-5
12. The ALS Association. ALS in the military. https://www.als.org/navigating-als/military-veterans/ALS-in-the-Military
13. McKay KA et al. Acta Neurol Scand. 2021;143(1):39-50. doi:10.1111/ane.13345
14. Lund EM et al. Muscle Nerve. 2021;63(6):807-811. doi:10.1002/mus.27181
15. Galea MD et al. Muscle Nerve. 2021;64(4):E18-E20. doi:10.1002/mus.27373
16. Re DB et al. J Neurol. 2022;269(5):2359-2377. doi:10.1007/s00415-021-10928-5
Data Trends 2023: Alzheimer’s and Dementia
6. Zhu CW, Sano M. Front Psychiatry. 2021;12:610334. doi:10.3389/fpsyt.2021.610334
7. Nianogo RA et al. JAMA Neurol. 2022;79(6):584-591. doi:10.1001/jamaneurol.2022.0976
8. Logue MW et al. Alzheimers Dement. 2022 Dec 22. Online ahead of print. doi:10.1002/alz.12870
9. Kempuraj D et al. Clin Ther. 2020;42(6):974-982. doi:10.1016/j.clinthera.2020.02.018
10. Martinez S et al. JAMA Neurol. 2021;78(4):473-477. doi:10.1001/jamaneurol.2020.5011
11. Verger A et al. Eur J Nucl Med Mol Imaging. 2023;50(6):1553-1555. doi:10.1007/s00259-023-06177-5
6. Zhu CW, Sano M. Front Psychiatry. 2021;12:610334. doi:10.3389/fpsyt.2021.610334
7. Nianogo RA et al. JAMA Neurol. 2022;79(6):584-591. doi:10.1001/jamaneurol.2022.0976
8. Logue MW et al. Alzheimers Dement. 2022 Dec 22. Online ahead of print. doi:10.1002/alz.12870
9. Kempuraj D et al. Clin Ther. 2020;42(6):974-982. doi:10.1016/j.clinthera.2020.02.018
10. Martinez S et al. JAMA Neurol. 2021;78(4):473-477. doi:10.1001/jamaneurol.2020.5011
11. Verger A et al. Eur J Nucl Med Mol Imaging. 2023;50(6):1553-1555. doi:10.1007/s00259-023-06177-5
6. Zhu CW, Sano M. Front Psychiatry. 2021;12:610334. doi:10.3389/fpsyt.2021.610334
7. Nianogo RA et al. JAMA Neurol. 2022;79(6):584-591. doi:10.1001/jamaneurol.2022.0976
8. Logue MW et al. Alzheimers Dement. 2022 Dec 22. Online ahead of print. doi:10.1002/alz.12870
9. Kempuraj D et al. Clin Ther. 2020;42(6):974-982. doi:10.1016/j.clinthera.2020.02.018
10. Martinez S et al. JAMA Neurol. 2021;78(4):473-477. doi:10.1001/jamaneurol.2020.5011
11. Verger A et al. Eur J Nucl Med Mol Imaging. 2023;50(6):1553-1555. doi:10.1007/s00259-023-06177-5
Allergic Contact Dermatitis
THE COMPARISON
A An 11-year-old Hispanic boy with allergic contact dermatitis (ACD) on the abdomen. The geometric nature of the eruption and proximity to the belt buckle were highly suggestive of ACD to nickel; patch testing was not needed.
B A Black woman with ACD on the neck. A punch biopsy demonstrated spongiotic dermatitis that was typical of ACD. The diagnosis was supported by the patient’s history of dermatitis that developed after new products were applied to the hair. The patient declined patch testing.
C A Hispanic man with ACD on hair-bearing areas on the face where hair dye was used. The patient’s history of dermatitis following the application of hair dye was highly suggestive of ACD; patch testing confirmed the allergen was paraphenylenediamine (PPD).
Allergic contact dermatitis (ACD) is an inflammatory condition of the skin caused by an immunologic response to one or more identifiable allergens. A delayed-type immune response (type IV hypersensitivity reaction) occurs after the skin is reexposed to an offending allergen.1 Severe pruritus is the main symptom of ACD in the early stages, accompanied by erythema, vesicles, and scaling in a distinct pattern corresponding to the allergen’s contact with the skin.2 Delayed widespread dermatitis after exposure to an allergen—a phenomenon known as autoeczematization (id reaction)—also may occur.3
The gold-standard diagnostic tool for ACD is patch testing, in which the patient is re-exposed to the suspected contact allergen(s) and observed for the development of dermatitis.4 However, ACD can be diagnosed with a detailed patient history including occupation, hobbies, personal care practices, and possible triggers with subsequent rashes. Thorough clinical examination of the skin is paramount. Indicators of possible ACD include dermatitis that persists despite use of appropriate treatment, an unexplained flare of previously quiescent dermatitis, and a diagnosis of dermatitis without a clear cause.1
Hairdressers, health care workers, and metal workers are at higher risk for ACD.5 Occupational ACD has notable socioeconomic implications, as it can result in frequent sick days, inability to perform tasks at work, and in some cases job loss.6
Patients with atopic dermatitis have impaired barrier function of the skin, permitting the entrance of allergens and subsequent sensitization.7 Allergic contact dermatitis is a challenge to manage, as complete avoidance of the allergen may not be possible.8
The underrepresentation of patients with skin of color (SOC) in educational materials as well as socioeconomic health disparities may contribute to the lower rates of diagnosis, patch testing, and treatment of ACD in this patient population.
Epidemiology
An ACD prevalence of 15.2% was reported in a study of 793 Danish patients who underwent skin prick and patch testing.9 Alinaghi et al10 conducted a meta-analysis of 20,107 patients across 28 studies who were patch tested to determine the prevalence of ACD in the general population. The researchers concluded that 20.1% (95% CI, 16.8%- 23.7%) of the general population experienced ACD. They analyzed 22 studies to determine the prevalence of ACD based on specific geographic area including 18,709 individuals from Europe with a prevalence of 19.5% (95% CI, 15.8%-23.4%), 1639 individuals from North America with a prevalence of 20.6% (95% CI, 9.2%-35.2%), and 2 studies from China (no other studies from Asia found) with a prevalence of 20.6% (95% CI, 17.4%-23.9%). Researchers did not find data from studies conducted in Africa or South America.10
The current available epidemiologic data on ACD are not representative of SOC populations. DeLeo et al11 looked at patch test reaction patterns in association with race and ethnicity in a large sample size (N=19,457); 17,803 (92.9%) of these patients were White and only 1360 (7.1%) were Black. Large-scale, inclusive studies are needed, which can only be achieved with increased suspicion for ACD and increased access to patch testing.
Allergic contact dermatitis is more common in women, with nickel being the most frequently identified allergen (Figure, A).10 Personal care products often are linked to ACD (Figure, B). An analysis of data from the North American Contact Dermatitis Group revealed that the top 5 personal care product allergens were methylisothiazolinone (a preservative), fragrance mix I, balsam of Peru, quaternium-15 (a preservative), and paraphenylenediamine (PPD)(a common component of hair dye) (Figure, C).12
There is a paucity of epidemiologic data among various ethnic groups; however, a few studies have suggested that there is no difference in the frequency rates of positive patch test results in Black vs White populations.11,13,14 One study of patch test results from 114 Black patients and 877 White patients at the Cleveland Clinic Foundation in Ohio demonstrated a similar allergy frequency of 43.0% and 43.6%, respectively.13 However, there were differences in the types of allergen sensitization. Black patients had higher positive patch test rates for PPD than White patients (10.6% vs 4.5%). Black men had a higher frequency of sensitivity to PPD (21.2% vs 4.2%) and imidazolidinyl urea (a formaldehyde-releasing preservative) (9.1% vs 2.6%) compared to White men.13
Ethnicity and cultural practices influence epidemiologic patterns of ACD. Darker hair dyes used in Black patients14 and deeply pigmented PPD dye found in henna tattoos used in Indian and Black patients15 may lead to increased sensitization to PPD. Allergic contact dermatitis due to formaldehyde is more common in White patients, possibly due to more frequent use of formaldehyde-containing moisturizers, shampoos, and creams.15
Key clinical features in people with darker skin tones
In patients with SOC, the clinical features of ACD vary, posing a diagnostic challenge. Hyperpigmentation, lichenification, and induration are more likely to be seen than the papules, vesicles, and erythematous dermatitis often described in lighter skin tones or acute ACD. Erythema can be difficult to assess on darker skin and may appear violaceous or very faint pink.16
Worth noting
A high index of suspicion is necessary when interpreting patch tests in patients with SOC, as patch test kits use a reading plate with graduated intensities of erythema, papulation, and vesicular reactions to determine the likelihood of ACD. The potential contact allergens are placed on the skin on day 1 and covered. Then, on day 3 the allergens are removed. The skin is clinically evaluated using visual assessment and skin palpation. The reactions are graded as negative, irritant reaction, equivocal, weak positive, strong positive, or extreme reaction at around days 3 and 5 to capture both early and delayed reactions.17 A patch test may be positive even if obvious signs of erythema are not appreciated as expected.
Adjusting the lighting in the examination room, including side lighting, or using a blue background can be helpful in identifying erythema in darker skin tones.15,16,18 Palpation of the skin also is useful, as even slight texture changes and induration are indicators of a possible skin reaction to the test allergen.15
Health disparity highlight
Clinical photographs of ACD and patch test results in patients with SOC are not commonplace in the literature. Positive patch test results in patients with darker skin tones vary from those of patients with lighter skin tones, and if the clinician reading the patch test result is not familiar with the findings in darker skin tones, the diagnosis may be delayed or missed.15
Furthermore, Scott et al15 highlighted that many dermatology residency training programs have a paucity of SOC education in their curriculum. This lack of representation may contribute to the diagnostic challenges encountered by health care providers.
Timely access to health care and education as well as economic stability are essential for the successful management of patients with ACD. Some individuals with SOC have been disproportionately affected by social determinants of health. Rodriguez-Homs et al19 demonstrated that the distance needed to travel to a clinic and the poverty rate of the county the patient lives in play a role in referral to a clinician specializing in contact dermatitis.
A retrospective registry review of 2310 patients undergoing patch testing at the Massachusetts General Hospital in Boston revealed that 2.5% were Black, 5.5% were Latinx, 8.3% were Asian, and the remaining 83.7% were White.20 Qian et al21 also looked at patch testing patterns among various sociodemographic groups (N=1,107,530) and found that 69% of patients were White and 59% were female. Rates of patch testing among patients who were Black, lesser educated, male, lower income, and younger (children aged 0–12 years) were significantly lower than for other groups when ACD was suspected (P<.0001).21 The lower rates of patch testing in patients with SOC may be due to low suspicion of diagnosis, low referral rates due to limited medical insurance, and financial instability, as well as other socioeconomic factors.20
Tamazian et al16 reviewed pediatric populations at 13 US centers and found that Black children received patch testing less frequently than White and Hispanic children. Another review of pediatric patch testing in patients with SOC found that a less comprehensive panel of allergens was used in this population.22
The key to resolution of ACD is removal of the offending antigen, and if patients are not being tested, then they risk having a prolonged and complicated course of ACD with a poor prognosis. Patients with SOC also experience greater negative psychosocial impact due to ACD disease burden.21,23
The lower rates of patch testing in Black patients cannot solely be attributed to difficulty diagnosing ACD in darker skin tones; it is likely due to the impact of social determinants of health. Alleviating health disparities will improve patient outcomes and quality of life.
- Mowad CM, Anderson B, Scheinman P, et al. Allergic contact dermatitis: patient diagnosis and evaluation. J Am Acad Dermatol. 2016;74: 1029-1040. doi:10.1016/j.jaad.2015.02.1139
- Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. 2010;82:249-255.
- Bertoli MJ, Schwartz RA, Janniger CK. Autoeczematization: a strange id reaction of the skin. Cutis. 2021;108:163-166. doi:10.12788/cutis.0342
- Johansen JD, Bonefeld CM, Schwensen JFB, et al. Novel insights into contact dermatitis. J Allergy Clin Immunol. 2022;149:1162-1171. doi:10.1016/j.jaci.2022.02.002
- Karagounis TK, Cohen DE. Occupational hand dermatitis. Curr Allergy Asthma Rep. 2023;23:201-212. doi:10.1007/s11882-023-01070-5
- Cvetkovski RS, Rothman KJ, Olsen J, et al. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. Br J Dermatol. 2005;152:93-98. doi:10.1111/j .1365-2133.2005.06415.x
- Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol. 2018;19:293-302. doi:10.1007/s40257-017-0340-7
- Brites GS, Ferreira I, Sebastião AI, et al. Allergic contact dermatitis: from pathophysiology to development of new preventive strategies. Pharmacol Res. 2020;162:105282. doi:10.1016/j.phrs.2020.105282
- Nielsen NH, Menne T. The relationship between IgE‐mediated and cell‐mediated hypersensitivities in an unselected Danish population: the Glostrup Allergy Study, Denmark. Br J Dermatol. 1996;134:669-672. doi:10.1111/j.1365-2133.1996.tb06967.x
- Alinaghi F, Bennike NH, Egeberg A, et al. Prevalence of contact allergy in the general population: a systematic review and meta‐analysis. Contact Dermatitis. 2019;80:77-85. doi:10.1111/cod.13119
- DeLeo VA, Alexis A, Warshaw EM, et al. The association of race/ethnicity and patch test results: North American Contact Dermatitis Group, 1998- 2006. Dermatitis. 2016;27:288-292. doi:10.1097/DER.0000000000000220
- Warshaw EM, Schlarbaum JP, Silverberg JI, et al. Contact dermatitis to personal care products is increasing (but different!) in males and females: North American Contact Dermatitis Group data, 1996-2016. J Am Acad Dermatol. 2021;85:1446-1455. doi:10.1016/j.jaad.2020.10.003
- Dickel H, Taylor JS, Evey P, et al. Comparison of patch test results with a standard series among white and black racial groups. Am J Contact Dermatol. 2001;12:77-82. doi:10.1053/ajcd.2001.20110
- DeLeo VA, Taylor SC, Belsito DV, et al. The effect of race and ethnicity on patch test results. J Am Acad Dermatol. 2002;46(2 suppl):S107-S112. doi:10.1067/mjd.2002.120792
- Scott I, Atwater AR, Reeder M. Update on contact dermatitis and patch testing in patients with skin of color. Cutis. 2021;108:10-12. doi:10.12788/cutis.0292
- Tamazian S, Oboite M, Treat JR. Patch testing in skin of color: a brief report. Pediatr Dermatol. 2021;38:952-953. doi:10.1111/pde.14578
- Litchman G, Nair PA, Atwater AR, et al. Contact dermatitis. StatPearls [Internet]. Updated February 9, 2023. Accessed September 25, 2023. https://www.ncbi.nlm.nih.gov/books/NBK459230/
- Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. J Am Acad Dermatol. 2019;80:1722-1729. doi:10.1016/j.jaad.2018.08.049
- Rodriguez-Homs LG, Liu B, Green CL, et al. Duration of dermatitis before patch test appointment is associated with distance to clinic and county poverty rate. Dermatitis. 2020;31:259-264. doi:10.1097 /DER.0000000000000581
- Foschi CM, Tam I, Schalock PC, et al. Patch testing results in skin of color: a retrospective review from the Massachusetts General Hospital contact dermatitis clinic. J Am Acad Dermatol. 2022;87:452-454. doi:10.1016/j.jaad.2021.09.022
- Qian MF, Li S, Honari G, et al. Sociodemographic disparities in patch testing for commercially insured patients with dermatitis: a retrospective analysis of administrative claims data. J Am Acad Dermatol. 2022;87:1411-1413. doi:10.1016/j.jaad.2022.08.041
- Young K, Collis RW, Sheinbein D, et al. Retrospective review of pediatric patch testing results in skin of color. J Am Acad Dermatol. 2023;88:953-954. doi:10.1016/j.jaad.2022.11.031
- Kadyk DL, Hall S, Belsito DV. Quality of life of patients with allergic contact dermatitis: an exploratory analysis by gender, ethnicity, age, and occupation. Dermatitis. 2004;15:117-124.
THE COMPARISON
A An 11-year-old Hispanic boy with allergic contact dermatitis (ACD) on the abdomen. The geometric nature of the eruption and proximity to the belt buckle were highly suggestive of ACD to nickel; patch testing was not needed.
B A Black woman with ACD on the neck. A punch biopsy demonstrated spongiotic dermatitis that was typical of ACD. The diagnosis was supported by the patient’s history of dermatitis that developed after new products were applied to the hair. The patient declined patch testing.
C A Hispanic man with ACD on hair-bearing areas on the face where hair dye was used. The patient’s history of dermatitis following the application of hair dye was highly suggestive of ACD; patch testing confirmed the allergen was paraphenylenediamine (PPD).
Allergic contact dermatitis (ACD) is an inflammatory condition of the skin caused by an immunologic response to one or more identifiable allergens. A delayed-type immune response (type IV hypersensitivity reaction) occurs after the skin is reexposed to an offending allergen.1 Severe pruritus is the main symptom of ACD in the early stages, accompanied by erythema, vesicles, and scaling in a distinct pattern corresponding to the allergen’s contact with the skin.2 Delayed widespread dermatitis after exposure to an allergen—a phenomenon known as autoeczematization (id reaction)—also may occur.3
The gold-standard diagnostic tool for ACD is patch testing, in which the patient is re-exposed to the suspected contact allergen(s) and observed for the development of dermatitis.4 However, ACD can be diagnosed with a detailed patient history including occupation, hobbies, personal care practices, and possible triggers with subsequent rashes. Thorough clinical examination of the skin is paramount. Indicators of possible ACD include dermatitis that persists despite use of appropriate treatment, an unexplained flare of previously quiescent dermatitis, and a diagnosis of dermatitis without a clear cause.1
Hairdressers, health care workers, and metal workers are at higher risk for ACD.5 Occupational ACD has notable socioeconomic implications, as it can result in frequent sick days, inability to perform tasks at work, and in some cases job loss.6
Patients with atopic dermatitis have impaired barrier function of the skin, permitting the entrance of allergens and subsequent sensitization.7 Allergic contact dermatitis is a challenge to manage, as complete avoidance of the allergen may not be possible.8
The underrepresentation of patients with skin of color (SOC) in educational materials as well as socioeconomic health disparities may contribute to the lower rates of diagnosis, patch testing, and treatment of ACD in this patient population.
Epidemiology
An ACD prevalence of 15.2% was reported in a study of 793 Danish patients who underwent skin prick and patch testing.9 Alinaghi et al10 conducted a meta-analysis of 20,107 patients across 28 studies who were patch tested to determine the prevalence of ACD in the general population. The researchers concluded that 20.1% (95% CI, 16.8%- 23.7%) of the general population experienced ACD. They analyzed 22 studies to determine the prevalence of ACD based on specific geographic area including 18,709 individuals from Europe with a prevalence of 19.5% (95% CI, 15.8%-23.4%), 1639 individuals from North America with a prevalence of 20.6% (95% CI, 9.2%-35.2%), and 2 studies from China (no other studies from Asia found) with a prevalence of 20.6% (95% CI, 17.4%-23.9%). Researchers did not find data from studies conducted in Africa or South America.10
The current available epidemiologic data on ACD are not representative of SOC populations. DeLeo et al11 looked at patch test reaction patterns in association with race and ethnicity in a large sample size (N=19,457); 17,803 (92.9%) of these patients were White and only 1360 (7.1%) were Black. Large-scale, inclusive studies are needed, which can only be achieved with increased suspicion for ACD and increased access to patch testing.
Allergic contact dermatitis is more common in women, with nickel being the most frequently identified allergen (Figure, A).10 Personal care products often are linked to ACD (Figure, B). An analysis of data from the North American Contact Dermatitis Group revealed that the top 5 personal care product allergens were methylisothiazolinone (a preservative), fragrance mix I, balsam of Peru, quaternium-15 (a preservative), and paraphenylenediamine (PPD)(a common component of hair dye) (Figure, C).12
There is a paucity of epidemiologic data among various ethnic groups; however, a few studies have suggested that there is no difference in the frequency rates of positive patch test results in Black vs White populations.11,13,14 One study of patch test results from 114 Black patients and 877 White patients at the Cleveland Clinic Foundation in Ohio demonstrated a similar allergy frequency of 43.0% and 43.6%, respectively.13 However, there were differences in the types of allergen sensitization. Black patients had higher positive patch test rates for PPD than White patients (10.6% vs 4.5%). Black men had a higher frequency of sensitivity to PPD (21.2% vs 4.2%) and imidazolidinyl urea (a formaldehyde-releasing preservative) (9.1% vs 2.6%) compared to White men.13
Ethnicity and cultural practices influence epidemiologic patterns of ACD. Darker hair dyes used in Black patients14 and deeply pigmented PPD dye found in henna tattoos used in Indian and Black patients15 may lead to increased sensitization to PPD. Allergic contact dermatitis due to formaldehyde is more common in White patients, possibly due to more frequent use of formaldehyde-containing moisturizers, shampoos, and creams.15
Key clinical features in people with darker skin tones
In patients with SOC, the clinical features of ACD vary, posing a diagnostic challenge. Hyperpigmentation, lichenification, and induration are more likely to be seen than the papules, vesicles, and erythematous dermatitis often described in lighter skin tones or acute ACD. Erythema can be difficult to assess on darker skin and may appear violaceous or very faint pink.16
Worth noting
A high index of suspicion is necessary when interpreting patch tests in patients with SOC, as patch test kits use a reading plate with graduated intensities of erythema, papulation, and vesicular reactions to determine the likelihood of ACD. The potential contact allergens are placed on the skin on day 1 and covered. Then, on day 3 the allergens are removed. The skin is clinically evaluated using visual assessment and skin palpation. The reactions are graded as negative, irritant reaction, equivocal, weak positive, strong positive, or extreme reaction at around days 3 and 5 to capture both early and delayed reactions.17 A patch test may be positive even if obvious signs of erythema are not appreciated as expected.
Adjusting the lighting in the examination room, including side lighting, or using a blue background can be helpful in identifying erythema in darker skin tones.15,16,18 Palpation of the skin also is useful, as even slight texture changes and induration are indicators of a possible skin reaction to the test allergen.15
Health disparity highlight
Clinical photographs of ACD and patch test results in patients with SOC are not commonplace in the literature. Positive patch test results in patients with darker skin tones vary from those of patients with lighter skin tones, and if the clinician reading the patch test result is not familiar with the findings in darker skin tones, the diagnosis may be delayed or missed.15
Furthermore, Scott et al15 highlighted that many dermatology residency training programs have a paucity of SOC education in their curriculum. This lack of representation may contribute to the diagnostic challenges encountered by health care providers.
Timely access to health care and education as well as economic stability are essential for the successful management of patients with ACD. Some individuals with SOC have been disproportionately affected by social determinants of health. Rodriguez-Homs et al19 demonstrated that the distance needed to travel to a clinic and the poverty rate of the county the patient lives in play a role in referral to a clinician specializing in contact dermatitis.
A retrospective registry review of 2310 patients undergoing patch testing at the Massachusetts General Hospital in Boston revealed that 2.5% were Black, 5.5% were Latinx, 8.3% were Asian, and the remaining 83.7% were White.20 Qian et al21 also looked at patch testing patterns among various sociodemographic groups (N=1,107,530) and found that 69% of patients were White and 59% were female. Rates of patch testing among patients who were Black, lesser educated, male, lower income, and younger (children aged 0–12 years) were significantly lower than for other groups when ACD was suspected (P<.0001).21 The lower rates of patch testing in patients with SOC may be due to low suspicion of diagnosis, low referral rates due to limited medical insurance, and financial instability, as well as other socioeconomic factors.20
Tamazian et al16 reviewed pediatric populations at 13 US centers and found that Black children received patch testing less frequently than White and Hispanic children. Another review of pediatric patch testing in patients with SOC found that a less comprehensive panel of allergens was used in this population.22
The key to resolution of ACD is removal of the offending antigen, and if patients are not being tested, then they risk having a prolonged and complicated course of ACD with a poor prognosis. Patients with SOC also experience greater negative psychosocial impact due to ACD disease burden.21,23
The lower rates of patch testing in Black patients cannot solely be attributed to difficulty diagnosing ACD in darker skin tones; it is likely due to the impact of social determinants of health. Alleviating health disparities will improve patient outcomes and quality of life.
THE COMPARISON
A An 11-year-old Hispanic boy with allergic contact dermatitis (ACD) on the abdomen. The geometric nature of the eruption and proximity to the belt buckle were highly suggestive of ACD to nickel; patch testing was not needed.
B A Black woman with ACD on the neck. A punch biopsy demonstrated spongiotic dermatitis that was typical of ACD. The diagnosis was supported by the patient’s history of dermatitis that developed after new products were applied to the hair. The patient declined patch testing.
C A Hispanic man with ACD on hair-bearing areas on the face where hair dye was used. The patient’s history of dermatitis following the application of hair dye was highly suggestive of ACD; patch testing confirmed the allergen was paraphenylenediamine (PPD).
Allergic contact dermatitis (ACD) is an inflammatory condition of the skin caused by an immunologic response to one or more identifiable allergens. A delayed-type immune response (type IV hypersensitivity reaction) occurs after the skin is reexposed to an offending allergen.1 Severe pruritus is the main symptom of ACD in the early stages, accompanied by erythema, vesicles, and scaling in a distinct pattern corresponding to the allergen’s contact with the skin.2 Delayed widespread dermatitis after exposure to an allergen—a phenomenon known as autoeczematization (id reaction)—also may occur.3
The gold-standard diagnostic tool for ACD is patch testing, in which the patient is re-exposed to the suspected contact allergen(s) and observed for the development of dermatitis.4 However, ACD can be diagnosed with a detailed patient history including occupation, hobbies, personal care practices, and possible triggers with subsequent rashes. Thorough clinical examination of the skin is paramount. Indicators of possible ACD include dermatitis that persists despite use of appropriate treatment, an unexplained flare of previously quiescent dermatitis, and a diagnosis of dermatitis without a clear cause.1
Hairdressers, health care workers, and metal workers are at higher risk for ACD.5 Occupational ACD has notable socioeconomic implications, as it can result in frequent sick days, inability to perform tasks at work, and in some cases job loss.6
Patients with atopic dermatitis have impaired barrier function of the skin, permitting the entrance of allergens and subsequent sensitization.7 Allergic contact dermatitis is a challenge to manage, as complete avoidance of the allergen may not be possible.8
The underrepresentation of patients with skin of color (SOC) in educational materials as well as socioeconomic health disparities may contribute to the lower rates of diagnosis, patch testing, and treatment of ACD in this patient population.
Epidemiology
An ACD prevalence of 15.2% was reported in a study of 793 Danish patients who underwent skin prick and patch testing.9 Alinaghi et al10 conducted a meta-analysis of 20,107 patients across 28 studies who were patch tested to determine the prevalence of ACD in the general population. The researchers concluded that 20.1% (95% CI, 16.8%- 23.7%) of the general population experienced ACD. They analyzed 22 studies to determine the prevalence of ACD based on specific geographic area including 18,709 individuals from Europe with a prevalence of 19.5% (95% CI, 15.8%-23.4%), 1639 individuals from North America with a prevalence of 20.6% (95% CI, 9.2%-35.2%), and 2 studies from China (no other studies from Asia found) with a prevalence of 20.6% (95% CI, 17.4%-23.9%). Researchers did not find data from studies conducted in Africa or South America.10
The current available epidemiologic data on ACD are not representative of SOC populations. DeLeo et al11 looked at patch test reaction patterns in association with race and ethnicity in a large sample size (N=19,457); 17,803 (92.9%) of these patients were White and only 1360 (7.1%) were Black. Large-scale, inclusive studies are needed, which can only be achieved with increased suspicion for ACD and increased access to patch testing.
Allergic contact dermatitis is more common in women, with nickel being the most frequently identified allergen (Figure, A).10 Personal care products often are linked to ACD (Figure, B). An analysis of data from the North American Contact Dermatitis Group revealed that the top 5 personal care product allergens were methylisothiazolinone (a preservative), fragrance mix I, balsam of Peru, quaternium-15 (a preservative), and paraphenylenediamine (PPD)(a common component of hair dye) (Figure, C).12
There is a paucity of epidemiologic data among various ethnic groups; however, a few studies have suggested that there is no difference in the frequency rates of positive patch test results in Black vs White populations.11,13,14 One study of patch test results from 114 Black patients and 877 White patients at the Cleveland Clinic Foundation in Ohio demonstrated a similar allergy frequency of 43.0% and 43.6%, respectively.13 However, there were differences in the types of allergen sensitization. Black patients had higher positive patch test rates for PPD than White patients (10.6% vs 4.5%). Black men had a higher frequency of sensitivity to PPD (21.2% vs 4.2%) and imidazolidinyl urea (a formaldehyde-releasing preservative) (9.1% vs 2.6%) compared to White men.13
Ethnicity and cultural practices influence epidemiologic patterns of ACD. Darker hair dyes used in Black patients14 and deeply pigmented PPD dye found in henna tattoos used in Indian and Black patients15 may lead to increased sensitization to PPD. Allergic contact dermatitis due to formaldehyde is more common in White patients, possibly due to more frequent use of formaldehyde-containing moisturizers, shampoos, and creams.15
Key clinical features in people with darker skin tones
In patients with SOC, the clinical features of ACD vary, posing a diagnostic challenge. Hyperpigmentation, lichenification, and induration are more likely to be seen than the papules, vesicles, and erythematous dermatitis often described in lighter skin tones or acute ACD. Erythema can be difficult to assess on darker skin and may appear violaceous or very faint pink.16
Worth noting
A high index of suspicion is necessary when interpreting patch tests in patients with SOC, as patch test kits use a reading plate with graduated intensities of erythema, papulation, and vesicular reactions to determine the likelihood of ACD. The potential contact allergens are placed on the skin on day 1 and covered. Then, on day 3 the allergens are removed. The skin is clinically evaluated using visual assessment and skin palpation. The reactions are graded as negative, irritant reaction, equivocal, weak positive, strong positive, or extreme reaction at around days 3 and 5 to capture both early and delayed reactions.17 A patch test may be positive even if obvious signs of erythema are not appreciated as expected.
Adjusting the lighting in the examination room, including side lighting, or using a blue background can be helpful in identifying erythema in darker skin tones.15,16,18 Palpation of the skin also is useful, as even slight texture changes and induration are indicators of a possible skin reaction to the test allergen.15
Health disparity highlight
Clinical photographs of ACD and patch test results in patients with SOC are not commonplace in the literature. Positive patch test results in patients with darker skin tones vary from those of patients with lighter skin tones, and if the clinician reading the patch test result is not familiar with the findings in darker skin tones, the diagnosis may be delayed or missed.15
Furthermore, Scott et al15 highlighted that many dermatology residency training programs have a paucity of SOC education in their curriculum. This lack of representation may contribute to the diagnostic challenges encountered by health care providers.
Timely access to health care and education as well as economic stability are essential for the successful management of patients with ACD. Some individuals with SOC have been disproportionately affected by social determinants of health. Rodriguez-Homs et al19 demonstrated that the distance needed to travel to a clinic and the poverty rate of the county the patient lives in play a role in referral to a clinician specializing in contact dermatitis.
A retrospective registry review of 2310 patients undergoing patch testing at the Massachusetts General Hospital in Boston revealed that 2.5% were Black, 5.5% were Latinx, 8.3% were Asian, and the remaining 83.7% were White.20 Qian et al21 also looked at patch testing patterns among various sociodemographic groups (N=1,107,530) and found that 69% of patients were White and 59% were female. Rates of patch testing among patients who were Black, lesser educated, male, lower income, and younger (children aged 0–12 years) were significantly lower than for other groups when ACD was suspected (P<.0001).21 The lower rates of patch testing in patients with SOC may be due to low suspicion of diagnosis, low referral rates due to limited medical insurance, and financial instability, as well as other socioeconomic factors.20
Tamazian et al16 reviewed pediatric populations at 13 US centers and found that Black children received patch testing less frequently than White and Hispanic children. Another review of pediatric patch testing in patients with SOC found that a less comprehensive panel of allergens was used in this population.22
The key to resolution of ACD is removal of the offending antigen, and if patients are not being tested, then they risk having a prolonged and complicated course of ACD with a poor prognosis. Patients with SOC also experience greater negative psychosocial impact due to ACD disease burden.21,23
The lower rates of patch testing in Black patients cannot solely be attributed to difficulty diagnosing ACD in darker skin tones; it is likely due to the impact of social determinants of health. Alleviating health disparities will improve patient outcomes and quality of life.
- Mowad CM, Anderson B, Scheinman P, et al. Allergic contact dermatitis: patient diagnosis and evaluation. J Am Acad Dermatol. 2016;74: 1029-1040. doi:10.1016/j.jaad.2015.02.1139
- Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. 2010;82:249-255.
- Bertoli MJ, Schwartz RA, Janniger CK. Autoeczematization: a strange id reaction of the skin. Cutis. 2021;108:163-166. doi:10.12788/cutis.0342
- Johansen JD, Bonefeld CM, Schwensen JFB, et al. Novel insights into contact dermatitis. J Allergy Clin Immunol. 2022;149:1162-1171. doi:10.1016/j.jaci.2022.02.002
- Karagounis TK, Cohen DE. Occupational hand dermatitis. Curr Allergy Asthma Rep. 2023;23:201-212. doi:10.1007/s11882-023-01070-5
- Cvetkovski RS, Rothman KJ, Olsen J, et al. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. Br J Dermatol. 2005;152:93-98. doi:10.1111/j .1365-2133.2005.06415.x
- Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol. 2018;19:293-302. doi:10.1007/s40257-017-0340-7
- Brites GS, Ferreira I, Sebastião AI, et al. Allergic contact dermatitis: from pathophysiology to development of new preventive strategies. Pharmacol Res. 2020;162:105282. doi:10.1016/j.phrs.2020.105282
- Nielsen NH, Menne T. The relationship between IgE‐mediated and cell‐mediated hypersensitivities in an unselected Danish population: the Glostrup Allergy Study, Denmark. Br J Dermatol. 1996;134:669-672. doi:10.1111/j.1365-2133.1996.tb06967.x
- Alinaghi F, Bennike NH, Egeberg A, et al. Prevalence of contact allergy in the general population: a systematic review and meta‐analysis. Contact Dermatitis. 2019;80:77-85. doi:10.1111/cod.13119
- DeLeo VA, Alexis A, Warshaw EM, et al. The association of race/ethnicity and patch test results: North American Contact Dermatitis Group, 1998- 2006. Dermatitis. 2016;27:288-292. doi:10.1097/DER.0000000000000220
- Warshaw EM, Schlarbaum JP, Silverberg JI, et al. Contact dermatitis to personal care products is increasing (but different!) in males and females: North American Contact Dermatitis Group data, 1996-2016. J Am Acad Dermatol. 2021;85:1446-1455. doi:10.1016/j.jaad.2020.10.003
- Dickel H, Taylor JS, Evey P, et al. Comparison of patch test results with a standard series among white and black racial groups. Am J Contact Dermatol. 2001;12:77-82. doi:10.1053/ajcd.2001.20110
- DeLeo VA, Taylor SC, Belsito DV, et al. The effect of race and ethnicity on patch test results. J Am Acad Dermatol. 2002;46(2 suppl):S107-S112. doi:10.1067/mjd.2002.120792
- Scott I, Atwater AR, Reeder M. Update on contact dermatitis and patch testing in patients with skin of color. Cutis. 2021;108:10-12. doi:10.12788/cutis.0292
- Tamazian S, Oboite M, Treat JR. Patch testing in skin of color: a brief report. Pediatr Dermatol. 2021;38:952-953. doi:10.1111/pde.14578
- Litchman G, Nair PA, Atwater AR, et al. Contact dermatitis. StatPearls [Internet]. Updated February 9, 2023. Accessed September 25, 2023. https://www.ncbi.nlm.nih.gov/books/NBK459230/
- Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. J Am Acad Dermatol. 2019;80:1722-1729. doi:10.1016/j.jaad.2018.08.049
- Rodriguez-Homs LG, Liu B, Green CL, et al. Duration of dermatitis before patch test appointment is associated with distance to clinic and county poverty rate. Dermatitis. 2020;31:259-264. doi:10.1097 /DER.0000000000000581
- Foschi CM, Tam I, Schalock PC, et al. Patch testing results in skin of color: a retrospective review from the Massachusetts General Hospital contact dermatitis clinic. J Am Acad Dermatol. 2022;87:452-454. doi:10.1016/j.jaad.2021.09.022
- Qian MF, Li S, Honari G, et al. Sociodemographic disparities in patch testing for commercially insured patients with dermatitis: a retrospective analysis of administrative claims data. J Am Acad Dermatol. 2022;87:1411-1413. doi:10.1016/j.jaad.2022.08.041
- Young K, Collis RW, Sheinbein D, et al. Retrospective review of pediatric patch testing results in skin of color. J Am Acad Dermatol. 2023;88:953-954. doi:10.1016/j.jaad.2022.11.031
- Kadyk DL, Hall S, Belsito DV. Quality of life of patients with allergic contact dermatitis: an exploratory analysis by gender, ethnicity, age, and occupation. Dermatitis. 2004;15:117-124.
- Mowad CM, Anderson B, Scheinman P, et al. Allergic contact dermatitis: patient diagnosis and evaluation. J Am Acad Dermatol. 2016;74: 1029-1040. doi:10.1016/j.jaad.2015.02.1139
- Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. 2010;82:249-255.
- Bertoli MJ, Schwartz RA, Janniger CK. Autoeczematization: a strange id reaction of the skin. Cutis. 2021;108:163-166. doi:10.12788/cutis.0342
- Johansen JD, Bonefeld CM, Schwensen JFB, et al. Novel insights into contact dermatitis. J Allergy Clin Immunol. 2022;149:1162-1171. doi:10.1016/j.jaci.2022.02.002
- Karagounis TK, Cohen DE. Occupational hand dermatitis. Curr Allergy Asthma Rep. 2023;23:201-212. doi:10.1007/s11882-023-01070-5
- Cvetkovski RS, Rothman KJ, Olsen J, et al. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. Br J Dermatol. 2005;152:93-98. doi:10.1111/j .1365-2133.2005.06415.x
- Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol. 2018;19:293-302. doi:10.1007/s40257-017-0340-7
- Brites GS, Ferreira I, Sebastião AI, et al. Allergic contact dermatitis: from pathophysiology to development of new preventive strategies. Pharmacol Res. 2020;162:105282. doi:10.1016/j.phrs.2020.105282
- Nielsen NH, Menne T. The relationship between IgE‐mediated and cell‐mediated hypersensitivities in an unselected Danish population: the Glostrup Allergy Study, Denmark. Br J Dermatol. 1996;134:669-672. doi:10.1111/j.1365-2133.1996.tb06967.x
- Alinaghi F, Bennike NH, Egeberg A, et al. Prevalence of contact allergy in the general population: a systematic review and meta‐analysis. Contact Dermatitis. 2019;80:77-85. doi:10.1111/cod.13119
- DeLeo VA, Alexis A, Warshaw EM, et al. The association of race/ethnicity and patch test results: North American Contact Dermatitis Group, 1998- 2006. Dermatitis. 2016;27:288-292. doi:10.1097/DER.0000000000000220
- Warshaw EM, Schlarbaum JP, Silverberg JI, et al. Contact dermatitis to personal care products is increasing (but different!) in males and females: North American Contact Dermatitis Group data, 1996-2016. J Am Acad Dermatol. 2021;85:1446-1455. doi:10.1016/j.jaad.2020.10.003
- Dickel H, Taylor JS, Evey P, et al. Comparison of patch test results with a standard series among white and black racial groups. Am J Contact Dermatol. 2001;12:77-82. doi:10.1053/ajcd.2001.20110
- DeLeo VA, Taylor SC, Belsito DV, et al. The effect of race and ethnicity on patch test results. J Am Acad Dermatol. 2002;46(2 suppl):S107-S112. doi:10.1067/mjd.2002.120792
- Scott I, Atwater AR, Reeder M. Update on contact dermatitis and patch testing in patients with skin of color. Cutis. 2021;108:10-12. doi:10.12788/cutis.0292
- Tamazian S, Oboite M, Treat JR. Patch testing in skin of color: a brief report. Pediatr Dermatol. 2021;38:952-953. doi:10.1111/pde.14578
- Litchman G, Nair PA, Atwater AR, et al. Contact dermatitis. StatPearls [Internet]. Updated February 9, 2023. Accessed September 25, 2023. https://www.ncbi.nlm.nih.gov/books/NBK459230/
- Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. J Am Acad Dermatol. 2019;80:1722-1729. doi:10.1016/j.jaad.2018.08.049
- Rodriguez-Homs LG, Liu B, Green CL, et al. Duration of dermatitis before patch test appointment is associated with distance to clinic and county poverty rate. Dermatitis. 2020;31:259-264. doi:10.1097 /DER.0000000000000581
- Foschi CM, Tam I, Schalock PC, et al. Patch testing results in skin of color: a retrospective review from the Massachusetts General Hospital contact dermatitis clinic. J Am Acad Dermatol. 2022;87:452-454. doi:10.1016/j.jaad.2021.09.022
- Qian MF, Li S, Honari G, et al. Sociodemographic disparities in patch testing for commercially insured patients with dermatitis: a retrospective analysis of administrative claims data. J Am Acad Dermatol. 2022;87:1411-1413. doi:10.1016/j.jaad.2022.08.041
- Young K, Collis RW, Sheinbein D, et al. Retrospective review of pediatric patch testing results in skin of color. J Am Acad Dermatol. 2023;88:953-954. doi:10.1016/j.jaad.2022.11.031
- Kadyk DL, Hall S, Belsito DV. Quality of life of patients with allergic contact dermatitis: an exploratory analysis by gender, ethnicity, age, and occupation. Dermatitis. 2004;15:117-124.
Reticular Hyperpigmentation With Keratotic Papules in the Axillae and Groin
The Diagnosis: Galli-Galli Disease
Several cutaneous conditions can present as reticulated hyperpigmentation or keratotic papules. Although genetic testing can help identify some of these dermatoses, biopsy typically is sufficient for diagnosis, and genetic testing can be considered for more clinically challenging cases. In our case, the clinical evidence and histopathologic findings were diagnostic of Galli-Galli disease (GGD), an autosomal-dominant genodermatosis with incomplete penetrance. Our patient was unaware of any family members with a diagnosis of GGD; however, she reported a great uncle with similar clinical findings.
Galli-Galli disease is a rare allelic variant of Dowling- Degos disease (DDD), both caused by a loss-of-function mutation in the keratin 5 gene, KRT5. Both conditions present as reticulated papules distributed symmetrically in the flexural regions, most commonly the axillae and groin, but also as comedolike papules, typically in patients aged 30 to 50 years.1 Cutaneous lesions primarily are of cosmetic concern but can be extremely pruritic, especially for patients with GGD. Gene mutations in protein O-fucosyltransferase 1, POFUT1; protein O-glucosyltransferase 1, POGLUT1; and presenilin enhancer 2, PSENEN, also have been discovered in cases of DDD and GGD.2,3
Galli-Galli disease and DDD are distinguishable by their histologic appearance. Both diseases show elongated fingerlike rete ridges and a thin suprapapillary epidermis. The basal projections often are described as bulbous or resembling antler horns.4 Galli-Galli disease can be differentiated from DDD by focal suprabasal acantholysis with minimal dyskeratosis (quiz images).5 Due to the genetic and clinical similarities, many consider GGD an acantholytic variant of DDD rather than its own entity. Indeed, some patients have shown acantholysis in one area of biopsy but not others.6
Hailey-Hailey disease (HHD)(also known as benign familial or benign chronic pemphigus) is an autosomaldominant disorder caused by mutation of the ATPase secretory pathway Ca2+ transporting 1 gene, ATP2C1. Clinically, patients tend to present at a wide age range with fragile flaccid vesicles that commonly develop on the neck, axillae, and groin. Histologically, the epidermis is acanthotic with a dilapidated brick wall– like appearance from a few persistent intercellular connections amid widespread acantholysis (Figure 1).7 Unlike in autoimmune pemphigus, direct immunofluorescence is negative, and acantholysis spares the adnexal structures. Hailey-Hailey disease does not involve reticulated hyperpigmentation or the elongated bulbous rete seen in GGD. Confluent and reticulated papillomatosis is a rare, typically asymptomatic, hyperpigmented dermatosis. It presents as a conglomeration of scaly hyperpigmented macules or papillomatous papules that coalesce centrally and are reticulated toward the periphery.
Confluent and reticulated papillomatosis most commonly is seen on the trunk, initially presenting in adolescents and young adults. Confluent and reticulated papillomatosis is histologically similar to acanthosis nigricans. Histopathology will show hyperkeratosis, papillomatosis, and minimal to no inflammatory infiltrate, with no elongated rete ridges or acantholysis (Figure 2).8
Pemphigus vulgaris is a blistering disease resulting from the development of autoantibodies against desmogleins 1 and 3. Similar to GGD, there is suprabasal acantholysis, which often results in a tombstonelike appearance consisting of separation between the basal layer cells of the epidermis but with maintained attachment to the underlying basement membrane zone. Unlike HHD, the acantholysis tends to involve the follicular epithelium in pemphigus vulgaris (Figure 3). Clinically, the blisters are positive for Nikolsky sign and can be both cutaneous or mucosal, commonly arising initially in the mouth during the fourth or fifth decades of life. Ruptured blisters can result in painful and hemorrhagic erosions.9 Direct immunofluorescence exhibits a classic chicken wire–like deposition of IgG and C3 between keratinocytes of the epidermis. Although sometimes difficult to appreciate, the deposition can be more prominent in the lower epidermis, in contrast to pemphigus foliaceus, which can have more prominent deposition in the upper epidermis.
Darier disease (or dyskeratosis follicularis) is an autosomal-dominant genodermatosis caused by mutation of the ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 gene, ATP2A2. Clinically, this disorder arises in adolescents as red-brown, greasy, crusted papules in seborrheic areas that may coalesce into papillomatous clusters. Palmar punctate keratoses and pits also are common. Histologically, Darier disease can appear similar to GGD, as both can show acantholysis and dyskeratosis. Darier disease will tend to show more prominent dyskeratosis with corps ronds and grains, as well as thicker villilike projections of keratinocytes into the papillary dermis, in contrast to the thinner, fingerlike or bulbous projections that hang down from the epidermis in GGD (Figure 4).10
- Hanneken S, Rütten A, Eigelshoven S, et al. Morbus Galli-Galli. Hautarzt. 2013;64:282.
- Wilson NJ, Cole C, Kroboth K, et al. Mutations in POGLUT1 in Galli- Galli/Dowling-Degos disease. Br J Dermatol. 2017;176:270-274.
- Ralser DJ, Basmanav FB, Tafazzoli A, et al. Mutations in γ-secretase subunit–encoding PSENEN underlie Dowling-Degos disease associated with acne inversa. J Clin Invest. 2017;127:1485-1490.
- Desai CA, Virmani N, Sakhiya J, et al. An uncommon presentation of Galli-Galli disease. Indian J Dermatol Venereol Leprol. 2016; 82:720-723.
- Joshi TP, Shaver S, Tschen J. Exacerbation of Galli-Galli disease following dialysis treatment: a case report and review of aggravating factors. Cureus. 2021;13:E15401.
- Muller CS, Pfohler C, Tilgen W. Changing a concept—controversy on the confusion spectrum of the reticulate pigmented disorders of the skin. J Cutan Pathol. 2008;36:44-48.
- Dai Y, Yu L, Wang Y, et al. Case report: a case of Hailey-Hailey disease mimicking condyloma acuminatum and a novel splice-site mutation of ATP2C1 gene. Front Genet. 2021;12:777630.
- Banjar TA, Abdulwahab RA, Al Hawsawi KA. Confluent and reticulated papillomatosis of Gougerot and Carteaud: a case report and review of the literature. Cureus. 2022;14:E24557.
- Porro AM, Seque CA, Ferreira MCC, et al. Pemphigus vulgaris. An Bras Dermatol. 2019;94:264-278.
- Bachar-Wikström E, Wikström JD. Darier disease—a multi-organ condition? Acta Derm Venereol. 2021;101:adv00430.
The Diagnosis: Galli-Galli Disease
Several cutaneous conditions can present as reticulated hyperpigmentation or keratotic papules. Although genetic testing can help identify some of these dermatoses, biopsy typically is sufficient for diagnosis, and genetic testing can be considered for more clinically challenging cases. In our case, the clinical evidence and histopathologic findings were diagnostic of Galli-Galli disease (GGD), an autosomal-dominant genodermatosis with incomplete penetrance. Our patient was unaware of any family members with a diagnosis of GGD; however, she reported a great uncle with similar clinical findings.
Galli-Galli disease is a rare allelic variant of Dowling- Degos disease (DDD), both caused by a loss-of-function mutation in the keratin 5 gene, KRT5. Both conditions present as reticulated papules distributed symmetrically in the flexural regions, most commonly the axillae and groin, but also as comedolike papules, typically in patients aged 30 to 50 years.1 Cutaneous lesions primarily are of cosmetic concern but can be extremely pruritic, especially for patients with GGD. Gene mutations in protein O-fucosyltransferase 1, POFUT1; protein O-glucosyltransferase 1, POGLUT1; and presenilin enhancer 2, PSENEN, also have been discovered in cases of DDD and GGD.2,3
Galli-Galli disease and DDD are distinguishable by their histologic appearance. Both diseases show elongated fingerlike rete ridges and a thin suprapapillary epidermis. The basal projections often are described as bulbous or resembling antler horns.4 Galli-Galli disease can be differentiated from DDD by focal suprabasal acantholysis with minimal dyskeratosis (quiz images).5 Due to the genetic and clinical similarities, many consider GGD an acantholytic variant of DDD rather than its own entity. Indeed, some patients have shown acantholysis in one area of biopsy but not others.6
Hailey-Hailey disease (HHD)(also known as benign familial or benign chronic pemphigus) is an autosomaldominant disorder caused by mutation of the ATPase secretory pathway Ca2+ transporting 1 gene, ATP2C1. Clinically, patients tend to present at a wide age range with fragile flaccid vesicles that commonly develop on the neck, axillae, and groin. Histologically, the epidermis is acanthotic with a dilapidated brick wall– like appearance from a few persistent intercellular connections amid widespread acantholysis (Figure 1).7 Unlike in autoimmune pemphigus, direct immunofluorescence is negative, and acantholysis spares the adnexal structures. Hailey-Hailey disease does not involve reticulated hyperpigmentation or the elongated bulbous rete seen in GGD. Confluent and reticulated papillomatosis is a rare, typically asymptomatic, hyperpigmented dermatosis. It presents as a conglomeration of scaly hyperpigmented macules or papillomatous papules that coalesce centrally and are reticulated toward the periphery.
Confluent and reticulated papillomatosis most commonly is seen on the trunk, initially presenting in adolescents and young adults. Confluent and reticulated papillomatosis is histologically similar to acanthosis nigricans. Histopathology will show hyperkeratosis, papillomatosis, and minimal to no inflammatory infiltrate, with no elongated rete ridges or acantholysis (Figure 2).8
Pemphigus vulgaris is a blistering disease resulting from the development of autoantibodies against desmogleins 1 and 3. Similar to GGD, there is suprabasal acantholysis, which often results in a tombstonelike appearance consisting of separation between the basal layer cells of the epidermis but with maintained attachment to the underlying basement membrane zone. Unlike HHD, the acantholysis tends to involve the follicular epithelium in pemphigus vulgaris (Figure 3). Clinically, the blisters are positive for Nikolsky sign and can be both cutaneous or mucosal, commonly arising initially in the mouth during the fourth or fifth decades of life. Ruptured blisters can result in painful and hemorrhagic erosions.9 Direct immunofluorescence exhibits a classic chicken wire–like deposition of IgG and C3 between keratinocytes of the epidermis. Although sometimes difficult to appreciate, the deposition can be more prominent in the lower epidermis, in contrast to pemphigus foliaceus, which can have more prominent deposition in the upper epidermis.
Darier disease (or dyskeratosis follicularis) is an autosomal-dominant genodermatosis caused by mutation of the ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 gene, ATP2A2. Clinically, this disorder arises in adolescents as red-brown, greasy, crusted papules in seborrheic areas that may coalesce into papillomatous clusters. Palmar punctate keratoses and pits also are common. Histologically, Darier disease can appear similar to GGD, as both can show acantholysis and dyskeratosis. Darier disease will tend to show more prominent dyskeratosis with corps ronds and grains, as well as thicker villilike projections of keratinocytes into the papillary dermis, in contrast to the thinner, fingerlike or bulbous projections that hang down from the epidermis in GGD (Figure 4).10
The Diagnosis: Galli-Galli Disease
Several cutaneous conditions can present as reticulated hyperpigmentation or keratotic papules. Although genetic testing can help identify some of these dermatoses, biopsy typically is sufficient for diagnosis, and genetic testing can be considered for more clinically challenging cases. In our case, the clinical evidence and histopathologic findings were diagnostic of Galli-Galli disease (GGD), an autosomal-dominant genodermatosis with incomplete penetrance. Our patient was unaware of any family members with a diagnosis of GGD; however, she reported a great uncle with similar clinical findings.
Galli-Galli disease is a rare allelic variant of Dowling- Degos disease (DDD), both caused by a loss-of-function mutation in the keratin 5 gene, KRT5. Both conditions present as reticulated papules distributed symmetrically in the flexural regions, most commonly the axillae and groin, but also as comedolike papules, typically in patients aged 30 to 50 years.1 Cutaneous lesions primarily are of cosmetic concern but can be extremely pruritic, especially for patients with GGD. Gene mutations in protein O-fucosyltransferase 1, POFUT1; protein O-glucosyltransferase 1, POGLUT1; and presenilin enhancer 2, PSENEN, also have been discovered in cases of DDD and GGD.2,3
Galli-Galli disease and DDD are distinguishable by their histologic appearance. Both diseases show elongated fingerlike rete ridges and a thin suprapapillary epidermis. The basal projections often are described as bulbous or resembling antler horns.4 Galli-Galli disease can be differentiated from DDD by focal suprabasal acantholysis with minimal dyskeratosis (quiz images).5 Due to the genetic and clinical similarities, many consider GGD an acantholytic variant of DDD rather than its own entity. Indeed, some patients have shown acantholysis in one area of biopsy but not others.6
Hailey-Hailey disease (HHD)(also known as benign familial or benign chronic pemphigus) is an autosomaldominant disorder caused by mutation of the ATPase secretory pathway Ca2+ transporting 1 gene, ATP2C1. Clinically, patients tend to present at a wide age range with fragile flaccid vesicles that commonly develop on the neck, axillae, and groin. Histologically, the epidermis is acanthotic with a dilapidated brick wall– like appearance from a few persistent intercellular connections amid widespread acantholysis (Figure 1).7 Unlike in autoimmune pemphigus, direct immunofluorescence is negative, and acantholysis spares the adnexal structures. Hailey-Hailey disease does not involve reticulated hyperpigmentation or the elongated bulbous rete seen in GGD. Confluent and reticulated papillomatosis is a rare, typically asymptomatic, hyperpigmented dermatosis. It presents as a conglomeration of scaly hyperpigmented macules or papillomatous papules that coalesce centrally and are reticulated toward the periphery.
Confluent and reticulated papillomatosis most commonly is seen on the trunk, initially presenting in adolescents and young adults. Confluent and reticulated papillomatosis is histologically similar to acanthosis nigricans. Histopathology will show hyperkeratosis, papillomatosis, and minimal to no inflammatory infiltrate, with no elongated rete ridges or acantholysis (Figure 2).8
Pemphigus vulgaris is a blistering disease resulting from the development of autoantibodies against desmogleins 1 and 3. Similar to GGD, there is suprabasal acantholysis, which often results in a tombstonelike appearance consisting of separation between the basal layer cells of the epidermis but with maintained attachment to the underlying basement membrane zone. Unlike HHD, the acantholysis tends to involve the follicular epithelium in pemphigus vulgaris (Figure 3). Clinically, the blisters are positive for Nikolsky sign and can be both cutaneous or mucosal, commonly arising initially in the mouth during the fourth or fifth decades of life. Ruptured blisters can result in painful and hemorrhagic erosions.9 Direct immunofluorescence exhibits a classic chicken wire–like deposition of IgG and C3 between keratinocytes of the epidermis. Although sometimes difficult to appreciate, the deposition can be more prominent in the lower epidermis, in contrast to pemphigus foliaceus, which can have more prominent deposition in the upper epidermis.
Darier disease (or dyskeratosis follicularis) is an autosomal-dominant genodermatosis caused by mutation of the ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 gene, ATP2A2. Clinically, this disorder arises in adolescents as red-brown, greasy, crusted papules in seborrheic areas that may coalesce into papillomatous clusters. Palmar punctate keratoses and pits also are common. Histologically, Darier disease can appear similar to GGD, as both can show acantholysis and dyskeratosis. Darier disease will tend to show more prominent dyskeratosis with corps ronds and grains, as well as thicker villilike projections of keratinocytes into the papillary dermis, in contrast to the thinner, fingerlike or bulbous projections that hang down from the epidermis in GGD (Figure 4).10
- Hanneken S, Rütten A, Eigelshoven S, et al. Morbus Galli-Galli. Hautarzt. 2013;64:282.
- Wilson NJ, Cole C, Kroboth K, et al. Mutations in POGLUT1 in Galli- Galli/Dowling-Degos disease. Br J Dermatol. 2017;176:270-274.
- Ralser DJ, Basmanav FB, Tafazzoli A, et al. Mutations in γ-secretase subunit–encoding PSENEN underlie Dowling-Degos disease associated with acne inversa. J Clin Invest. 2017;127:1485-1490.
- Desai CA, Virmani N, Sakhiya J, et al. An uncommon presentation of Galli-Galli disease. Indian J Dermatol Venereol Leprol. 2016; 82:720-723.
- Joshi TP, Shaver S, Tschen J. Exacerbation of Galli-Galli disease following dialysis treatment: a case report and review of aggravating factors. Cureus. 2021;13:E15401.
- Muller CS, Pfohler C, Tilgen W. Changing a concept—controversy on the confusion spectrum of the reticulate pigmented disorders of the skin. J Cutan Pathol. 2008;36:44-48.
- Dai Y, Yu L, Wang Y, et al. Case report: a case of Hailey-Hailey disease mimicking condyloma acuminatum and a novel splice-site mutation of ATP2C1 gene. Front Genet. 2021;12:777630.
- Banjar TA, Abdulwahab RA, Al Hawsawi KA. Confluent and reticulated papillomatosis of Gougerot and Carteaud: a case report and review of the literature. Cureus. 2022;14:E24557.
- Porro AM, Seque CA, Ferreira MCC, et al. Pemphigus vulgaris. An Bras Dermatol. 2019;94:264-278.
- Bachar-Wikström E, Wikström JD. Darier disease—a multi-organ condition? Acta Derm Venereol. 2021;101:adv00430.
- Hanneken S, Rütten A, Eigelshoven S, et al. Morbus Galli-Galli. Hautarzt. 2013;64:282.
- Wilson NJ, Cole C, Kroboth K, et al. Mutations in POGLUT1 in Galli- Galli/Dowling-Degos disease. Br J Dermatol. 2017;176:270-274.
- Ralser DJ, Basmanav FB, Tafazzoli A, et al. Mutations in γ-secretase subunit–encoding PSENEN underlie Dowling-Degos disease associated with acne inversa. J Clin Invest. 2017;127:1485-1490.
- Desai CA, Virmani N, Sakhiya J, et al. An uncommon presentation of Galli-Galli disease. Indian J Dermatol Venereol Leprol. 2016; 82:720-723.
- Joshi TP, Shaver S, Tschen J. Exacerbation of Galli-Galli disease following dialysis treatment: a case report and review of aggravating factors. Cureus. 2021;13:E15401.
- Muller CS, Pfohler C, Tilgen W. Changing a concept—controversy on the confusion spectrum of the reticulate pigmented disorders of the skin. J Cutan Pathol. 2008;36:44-48.
- Dai Y, Yu L, Wang Y, et al. Case report: a case of Hailey-Hailey disease mimicking condyloma acuminatum and a novel splice-site mutation of ATP2C1 gene. Front Genet. 2021;12:777630.
- Banjar TA, Abdulwahab RA, Al Hawsawi KA. Confluent and reticulated papillomatosis of Gougerot and Carteaud: a case report and review of the literature. Cureus. 2022;14:E24557.
- Porro AM, Seque CA, Ferreira MCC, et al. Pemphigus vulgaris. An Bras Dermatol. 2019;94:264-278.
- Bachar-Wikström E, Wikström JD. Darier disease—a multi-organ condition? Acta Derm Venereol. 2021;101:adv00430.
A 37-year-old woman presented with multiple hyperkeratotic small papules in the axillae and groin of 1 year’s duration. She reported pruritus and occasional sleep disruption. Subtle background reticulated hyperpigmentation was present. The patient reported that she had a great uncle with similar findings.
Data Trends 2023: Respiratory Illnesses
- Hines SE et al. Respir Med. 2022;202:106963. doi:10.1016/j.rmed.2022.106963
- Dursa EK et al. Am J Ind Med. 2020;63(11):980-987. doi:10.1002/ajim.23172
- Bamonti PM et al. Int J Chron Obstruct Pulmon Dis. 2022;17:1269-1283. doi:10.2147/COPD.S339323
- Hines SE et al. Respir Med. 2022;202:106963. doi:10.1016/j.rmed.2022.106963
- Dursa EK et al. Am J Ind Med. 2020;63(11):980-987. doi:10.1002/ajim.23172
- Bamonti PM et al. Int J Chron Obstruct Pulmon Dis. 2022;17:1269-1283. doi:10.2147/COPD.S339323
- Hines SE et al. Respir Med. 2022;202:106963. doi:10.1016/j.rmed.2022.106963
- Dursa EK et al. Am J Ind Med. 2020;63(11):980-987. doi:10.1002/ajim.23172
- Bamonti PM et al. Int J Chron Obstruct Pulmon Dis. 2022;17:1269-1283. doi:10.2147/COPD.S339323
Data Trends 2023: Pregnancy
9. Frayne SM et al. Sourcebook: Women Veterans in the Veterans Health Administration. Volume 4: Longitudinal Trends in Sociodemographics, Utilization, Health Profile, and Geographic Distribution. Women’s Health Evaluation Initiative, Women’s Health Services, Veterans Health Administration. Published 2018. Accessed May 5, 2023. https://www.womenshealth.va.gov/WOMENSHEALTH/materials-and-resources/publications-and-reports.asp
10. Katon J et al. J Womens Health (Larchmt). 2014;23(10):792-800. doi:10.1089/jwh.2013.4681
11. Day MA et al. Am J Orthopsychiatry. 2023;93(1):41-49. doi:10.1037/ort0000654
12. Shaw JG et al. Health Serv Res. 2018;53(suppl 3):5260-5284. doi:10.1111/1475-6773.13041
13. Shaw JG et al. Obstet Gynecol. 2014;124(6):1111-1119. doi:10.1097/AOG.0000000000000542
14. Shaw JG et al. Paediatr Perinat Epidemiol. 2017;31(3):185-194. doi:10.1111/ppe.12349
15. Kroll-Desrosiers A et al. J Gen Intern Med. 2022;37(suppl 3):762-769. doi:10.1007/s11606-022-07573-7
16. Creech SK et al. Depress Anxiety. 2022;39(3):201-210. doi:10.1002/da.23218
17. US Department of Defense. Department of Defense Releases Annual Demographics Report — Upward Trend in Number of Women Serving Continues. Published December 14, 2022. Accessed June 12, 2023. https://www.defense.gov/News/Releases/Release/Article/3246268/department-of-defense-releases-annual-demographics-report-upward-trend-in-numbe/
9. Frayne SM et al. Sourcebook: Women Veterans in the Veterans Health Administration. Volume 4: Longitudinal Trends in Sociodemographics, Utilization, Health Profile, and Geographic Distribution. Women’s Health Evaluation Initiative, Women’s Health Services, Veterans Health Administration. Published 2018. Accessed May 5, 2023. https://www.womenshealth.va.gov/WOMENSHEALTH/materials-and-resources/publications-and-reports.asp
10. Katon J et al. J Womens Health (Larchmt). 2014;23(10):792-800. doi:10.1089/jwh.2013.4681
11. Day MA et al. Am J Orthopsychiatry. 2023;93(1):41-49. doi:10.1037/ort0000654
12. Shaw JG et al. Health Serv Res. 2018;53(suppl 3):5260-5284. doi:10.1111/1475-6773.13041
13. Shaw JG et al. Obstet Gynecol. 2014;124(6):1111-1119. doi:10.1097/AOG.0000000000000542
14. Shaw JG et al. Paediatr Perinat Epidemiol. 2017;31(3):185-194. doi:10.1111/ppe.12349
15. Kroll-Desrosiers A et al. J Gen Intern Med. 2022;37(suppl 3):762-769. doi:10.1007/s11606-022-07573-7
16. Creech SK et al. Depress Anxiety. 2022;39(3):201-210. doi:10.1002/da.23218
17. US Department of Defense. Department of Defense Releases Annual Demographics Report — Upward Trend in Number of Women Serving Continues. Published December 14, 2022. Accessed June 12, 2023. https://www.defense.gov/News/Releases/Release/Article/3246268/department-of-defense-releases-annual-demographics-report-upward-trend-in-numbe/
9. Frayne SM et al. Sourcebook: Women Veterans in the Veterans Health Administration. Volume 4: Longitudinal Trends in Sociodemographics, Utilization, Health Profile, and Geographic Distribution. Women’s Health Evaluation Initiative, Women’s Health Services, Veterans Health Administration. Published 2018. Accessed May 5, 2023. https://www.womenshealth.va.gov/WOMENSHEALTH/materials-and-resources/publications-and-reports.asp
10. Katon J et al. J Womens Health (Larchmt). 2014;23(10):792-800. doi:10.1089/jwh.2013.4681
11. Day MA et al. Am J Orthopsychiatry. 2023;93(1):41-49. doi:10.1037/ort0000654
12. Shaw JG et al. Health Serv Res. 2018;53(suppl 3):5260-5284. doi:10.1111/1475-6773.13041
13. Shaw JG et al. Obstet Gynecol. 2014;124(6):1111-1119. doi:10.1097/AOG.0000000000000542
14. Shaw JG et al. Paediatr Perinat Epidemiol. 2017;31(3):185-194. doi:10.1111/ppe.12349
15. Kroll-Desrosiers A et al. J Gen Intern Med. 2022;37(suppl 3):762-769. doi:10.1007/s11606-022-07573-7
16. Creech SK et al. Depress Anxiety. 2022;39(3):201-210. doi:10.1002/da.23218
17. US Department of Defense. Department of Defense Releases Annual Demographics Report — Upward Trend in Number of Women Serving Continues. Published December 14, 2022. Accessed June 12, 2023. https://www.defense.gov/News/Releases/Release/Article/3246268/department-of-defense-releases-annual-demographics-report-upward-trend-in-numbe/
Federal Health Care Data Trends 2023
Federal Health Care Data Trends (click to view the digital edition) is a special supplement to Federal Practitioner, highlighting the latest research and study outcomes related to the health of veteran and active-duty populations.
In this issue:
- Limb Loss and Prostheses
- Neurology
- Cardiology
- Mental Health
- Diabetes
- Rheumatoid Arthritis
- Respiratory illnesses
- Women's Health
- HPV and Related Cancers
Federal Health Care Data Trends (click to view the digital edition) is a special supplement to Federal Practitioner, highlighting the latest research and study outcomes related to the health of veteran and active-duty populations.
In this issue:
- Limb Loss and Prostheses
- Neurology
- Cardiology
- Mental Health
- Diabetes
- Rheumatoid Arthritis
- Respiratory illnesses
- Women's Health
- HPV and Related Cancers
Federal Health Care Data Trends (click to view the digital edition) is a special supplement to Federal Practitioner, highlighting the latest research and study outcomes related to the health of veteran and active-duty populations.
In this issue:
- Limb Loss and Prostheses
- Neurology
- Cardiology
- Mental Health
- Diabetes
- Rheumatoid Arthritis
- Respiratory illnesses
- Women's Health
- HPV and Related Cancers